RNA治疗临床试验市场－全球产业规模、份额、趋势、机会及预测（按类型、阶段、治疗领域、地区及竞争格局划分，2021-2031年）

全球 RNA 治疗临床试验市场预计将从 2025 年的 31.7 亿美元成长到 2031 年的 42.8 亿美元，复合年增长率为 5.13%。

这个领域涉及对各种基于RNA的治疗方法（包括mRNA疫苗、反义寡核苷酸和RNA干扰疗法）在治疗遗传性和获得性疾病方面的安全性和有效性进行研究。成长要素的关键因素包括慢性病和罕见疾病发病率的上升，以及药物递送技术的显着进步，例如脂质奈米颗粒，这些技术能够提高药物稳定性和细胞吸收率。美国基因与细胞治疗学会（ASGCT）报告称，2025年第二季已有38项新的RNA疗法临床试验启动，这就是该领域研发管线稳定成长的例证。

然而，市场扩张的一大障碍在于难以有效针对肝臟以外的其他组织。 RNA分子固有的不稳定性，加上製造安全、高纯度递送系统的复杂性，为研发人员带来了巨大的技术和经济挑战。因此，解决这些稳定性和递送问题是获得监管部门核准和下一代RNA疗法成功商业化的关键前提。

市场驱动因素

推动全球RNA疗法临床试验市场发展的关键因素是创业投资和政府资金的大量涌入，这使得生物技术公司能够继续进行资本密集的研发活动。鑑于生产和安全性测试的高昂成本，这种资金支持对于将早期候选药物推进到后期临床试验至关重要。此外，资金的充足也促进了研发管线的多元化，使其不再局限于感染疾病，而是拓展至癌症治疗和罕见遗传疾病治疗，有助于降低系统性风险。为了证明投资者的韧性，再生医学联盟于2024年10月宣布，包括RNA疗法在内的更广泛的细胞和基因治疗领域在2024年上半年获得了109亿美元的投资。

同时，mRNA技术平台在疫情期间的成功，促使人们的关注点从预防性疫苗转向治疗性疫苗，为市场加速发展奠定了坚实的基础。 mRNA已被证实能够实现体内蛋白质生产，这降低了监管机构和投资者的风险，并促进了癌症免疫疗法和蛋白质替代策略等新型应用的研究。这种技术的成熟正在带来切实可见的监管成果，进一步加速临床应用。例如，2024年5月，Moderna公司宣布，美国食品药物管理局（FDA）核准了mRESVIA，一种用于预防60岁及以上成年人感染呼吸道融合细胞病毒（RSV）的疫苗。这是首个核准的非新冠病毒mRNA疫苗。此外，国际细胞与基因治疗学会（ISCT）报告称，2024年全年共有七种不同的细胞和基因治疗产品获得FDA核准，凸显了支持该市场的监管势头。

市场挑战

全球RNA疗法临床试验市场的主要障碍在于，将治疗药物有效地递送至肝臟以外的组织存在技术复杂性，以及RNA分子本身的不稳定性。虽然现有的递送系统（例如脂质奈米颗粒）对肝臟靶向有效，但将其应用于其他器官则需要复杂的设计，这往往会导致稳定性降低和毒性增加。这项限制迫使药物研发人员在复杂的生产流程上投入巨资，以确保递送系统的高纯度，从而显着增加研发成本并延长研发週期。因此，与稳定性和递送问题相关的临床试验失败风险增加，导致投资环境趋于谨慎，使得许多有前景的候选药物止步于临床前阶段，而未能进入人体试验阶段。

这项技术瓶颈显然正在减缓市场扩张的步伐。根据美国基因与细胞治疗学会（ASGCT）的数据显示，2025年第三季度，基因治疗、细胞治疗和RNA治疗等广泛领域的临床开发活动有所放缓，这些领域总合启动了125项试验。这一放缓表明，儘管人们对RNA疗法表现出浓厚的兴趣，但克服递送和稳定性障碍方面持续存在的困难阻碍了研究成果快速转化为临床试验，从而限制了市场的整体增长。

市场趋势

个人化mRNA癌症疫苗试验的加速推进，正从根本上改变市场格局，将传讯RNA技术的应用从感染疾病预防转向精准癌症治疗。借助疫情期间快速发展的生产能力，研发人员正在开发针对患者特异性肿瘤新抗原的个人化免疫疗法，以应对固体癌瘤的高復发率。同时，由于需要检验mRNA在复杂癌症病例中的治疗潜力，早期安全性试验正迅速推进至大规模疗效试验。为了支持这一积极成长，BioNTech在其2024年11月的财务报告中确认，其目标是在2024年底前开展超过10项有望进入临床实验註册阶段的癌症治疗产品试验，这标誌着后期研发工作将显着增加。

同时，RNA编辑疗法的临床计画拓展代表着该领域的一项重要进展，其发展方向已从基因静默和替换转向在转录层面上精确纠正基因突变。这种方法利用细胞内在机制，例如ADAR酶，在不永久改变基因组DNA的情况下暂时编辑RNA序列，与基于CRISPR的编辑方法相比，为治疗慢性遗传疾病提供了更安全的选择。近年来，该方法已从理论潜力走向临床检验，确立了一种新的治疗类别。例如，2024年10月，Wave Life Sciences公司报告了首个在人体中进行的治疗性RNA编辑研究－Ib/IIa期临床试验「RestorAATion-2」。接受WVE-006治疗的患者体内野生型M-AAT蛋白的平均恢復率超过总AAT蛋白的60%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球RNA疗法临床试验市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按方式（RNA干扰、反义疗法、传讯RNA、寡核苷酸、非反义、非RNAi）
  • 依研发阶段（I期、II期、III期、IV期）
  • 依治疗领域（罕见疾病、抗感染、抗癌、神经系统、胃肠道/代谢、肌肉骨骼、心血管/呼吸系统、感觉系统、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美RNA疗法临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲RNA疗法临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区RNA疗法临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲RNA疗法临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美RNA疗法临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球RNA疗法临床试验市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• IQVIA Inc.
• ICON Plc
• Laboratory Corporation of America Holdings
• Charles River Laboratories International, Inc.
• PAREXEL International Corp.
• Syneos Health
• Medpace Holdings, Inc.
• Novotech Inc.
• PPD Inc.
• Veristat, LLC.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global RNA Therapy Clinical Trials Market is projected to expand from USD 3.17 Billion in 2025 to USD 4.28 Billion by 2031, registering a compound annual growth rate of 5.13%. This sector encompasses research studies aimed at assessing the safety and effectiveness of various RNA-based treatments, such as mRNA vaccines, antisense oligonucleotides, and RNA interference therapies for both genetic and acquired conditions. Key growth drivers include the rising incidence of chronic and rare diseases, as well as significant advancements in delivery technologies like lipid nanoparticles, which improve the stability and cellular absorption of these drugs. Illustrating this consistent pipeline growth, the American Society of Gene & Cell Therapy reported that 38 new RNA therapy clinical trials were launched in the second quarter of 2025.

However, a significant obstacle to broader market expansion is the difficulty of successfully targeting tissues outside the liver. The natural instability of RNA molecules, combined with the intricacies of manufacturing safe, high-purity delivery systems, presents considerable technical and financial challenges for developers. Consequently, resolving these stability and distribution issues is a vital precondition for securing regulatory approval and achieving the successful commercialization of next-generation RNA therapeutics.

Market Driver

A major force driving the Global RNA Therapy Clinical Trials Market is the significant influx of venture capital and government funding, which empowers biotechnology companies to maintain capital-intensive research and development efforts. This financial support is crucial for advancing early-stage candidates into later clinical phases, given the substantial costs involved in manufacturing and safety testing. Furthermore, access to capital facilitates pipeline diversification beyond infectious diseases into areas like oncology and rare genetic disorders, thereby lowering systemic risk. As evidence of investor resilience, the Alliance for Regenerative Medicine noted in October 2024 that the broader cell and gene therapy sector, which includes RNA therapeutics, secured $10.9 billion in investment during the first half of the year.

In parallel, the proven success of mRNA technology platforms during the pandemic has created a strong basis for market acceleration, transitioning focus from prophylactic vaccines to therapeutic treatments. The demonstrated ability of mRNA to generate protein production in vivo has reduced risks for regulators and investors, prompting the investigation of novel uses such as cancer immunotherapies and protein replacement strategies. This technical maturity is resulting in tangible regulatory achievements that further boost clinical activity. For instance, Moderna reported in May 2024 that the U.S. FDA approved mRESVIA for protecting adults aged 60 and older against respiratory syncytial virus, the first non-COVID mRNA vaccine approval, while the International Society for Cell & Gene Therapy noted that seven distinct cell and gene therapy products received FDA approval throughout 2024, highlighting the regulatory momentum supporting this market.

Market Challenge

The principal hindrance to the Global RNA Therapy Clinical Trials Market is the technical complexity involved in delivering therapies effectively to tissues other than the liver, alongside the inherent instability of RNA molecules. Although existing delivery vehicles such as lipid nanoparticles work well for hepatic targets, adapting them for other organs necessitates complex engineering that often degrades stability or increases toxicity. This constraint compels pharmaceutical developers to invest heavily in intricate manufacturing processes to guarantee high-purity delivery systems, which significantly raises development costs and lengthens timelines. As a result, the elevated risk of clinical failure linked to these stability and distribution issues creates a hesitant investment climate, causing many potential candidates to stall in preclinical stages rather than progressing to human trials.

This technical bottleneck creates a measurable drag on the market's rate of expansion. According to the American Society of Gene & Cell Therapy, clinical development activity across the broader gene, cell, and RNA therapy landscape slowed in the third quarter of 2025, with a total of 125 trials initiated across these sectors. This deceleration suggests that despite significant interest in RNA therapeutics, the persistent difficulty in overcoming delivery and stability barriers is impeding the rapid translation of research into active clinical studies, thereby moderating the overall growth trajectory of the market.

Market Trends

The acceleration of personalized mRNA cancer vaccine trials is fundamentally transforming the market by shifting the application of messenger RNA technology from preventing infectious diseases to precision oncology. Developers are utilizing rapid manufacturing capabilities honed during the pandemic to create patient-specific immunotherapies targeting unique tumor neoantigens, aiming to address high recurrence rates in solid tumors. This trend involves a quick progression from early-phase safety studies to large-scale efficacy trials, driven by the necessity to validate the therapeutic potential of mRNA in complex cancer cases. Highlighting this aggressive growth, BioNTech confirmed in its November 2024 financial update an objective to have ten or more potentially registrational trials in its oncology pipeline by the end of 2024, indicating a substantial increase in late-stage development.

Simultaneously, the expansion of RNA-editing therapeutic clinical programs marks a significant evolution in the sector, advancing from gene silencing or replacement to the precise correction of genetic mutations at the transcript level. This method employs endogenous cellular machinery, such as ADAR enzymes, to transiently edit RNA sequences without permanently modifying genomic DNA, providing a safer alternative to CRISPR-based editing for chronic genetic disorders. This approach has recently moved from theoretical potential to clinical validation, confirming a new class of therapeutics. For example, Wave Life Sciences reported in October 2024 that its Phase 1b/2a RestorAATion-2 study achieved the first-ever therapeutic RNA editing in humans, with patients treated with WVE-006 showing a mean wild-type M-AAT protein restoration of over 60% of total AAT.

Key Market Players

• IQVIA Inc.
• ICON Plc
• Laboratory Corporation of America Holdings
• Charles River Laboratories International, Inc.
• PAREXEL International Corp.
• Syneos Health
• Medpace Holdings, Inc.
• Novotech Inc.
• PPD Inc.
• Veristat, LLC.

Report Scope

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Therapy Clinical Trials Market, By Modality

• RNA interference
• Antisense therapy
• Messenger RNA
• Oligonucleotide
• non-antisense
• non-RNAi

RNA Therapy Clinical Trials Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

RNA Therapy Clinical Trials Market, By Therapeutic Areas

• Rare Diseases
• Anti-infective
• Anticancer
• Neurological
• Alimentary/Metabolic
• Musculoskeletal
• Cardiovascular Respiratory
• Sensory
• Others

RNA Therapy Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Therapy Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
  • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America RNA Therapy Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Modality
  • 6.2.2. By Phase
  • 6.2.3. By Therapeutic Areas
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Therapy Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Modality
      • 6.3.1.2.2. By Phase
      • 6.3.1.2.3. By Therapeutic Areas
  • 6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Modality
      • 6.3.2.2.2. By Phase
      • 6.3.2.2.3. By Therapeutic Areas
  • 6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Modality
      • 6.3.3.2.2. By Phase
      • 6.3.3.2.3. By Therapeutic Areas

7. Europe RNA Therapy Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Modality
  • 7.2.2. By Phase
  • 7.2.3. By Therapeutic Areas
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Modality
      • 7.3.1.2.2. By Phase
      • 7.3.1.2.3. By Therapeutic Areas
  • 7.3.2. France RNA Therapy Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Modality
      • 7.3.2.2.2. By Phase
      • 7.3.2.2.3. By Therapeutic Areas
  • 7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Modality
      • 7.3.3.2.2. By Phase
      • 7.3.3.2.3. By Therapeutic Areas
  • 7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Modality
      • 7.3.4.2.2. By Phase
      • 7.3.4.2.3. By Therapeutic Areas
  • 7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Modality
      • 7.3.5.2.2. By Phase
      • 7.3.5.2.3. By Therapeutic Areas

8. Asia Pacific RNA Therapy Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Modality
  • 8.2.2. By Phase
  • 8.2.3. By Therapeutic Areas
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China RNA Therapy Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Modality
      • 8.3.1.2.2. By Phase
      • 8.3.1.2.3. By Therapeutic Areas
  • 8.3.2. India RNA Therapy Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Modality
      • 8.3.2.2.2. By Phase
      • 8.3.2.2.3. By Therapeutic Areas
  • 8.3.3. Japan RNA Therapy Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Modality
      • 8.3.3.2.2. By Phase
      • 8.3.3.2.3. By Therapeutic Areas
  • 8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Modality
      • 8.3.4.2.2. By Phase
      • 8.3.4.2.3. By Therapeutic Areas
  • 8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Modality
      • 8.3.5.2.2. By Phase
      • 8.3.5.2.3. By Therapeutic Areas

9. Middle East & Africa RNA Therapy Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Modality
  • 9.2.2. By Phase
  • 9.2.3. By Therapeutic Areas
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Modality
      • 9.3.1.2.2. By Phase
      • 9.3.1.2.3. By Therapeutic Areas
  • 9.3.2. UAE RNA Therapy Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Modality
      • 9.3.2.2.2. By Phase
      • 9.3.2.2.3. By Therapeutic Areas
  • 9.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Modality
      • 9.3.3.2.2. By Phase
      • 9.3.3.2.3. By Therapeutic Areas

10. South America RNA Therapy Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Modality
  • 10.2.2. By Phase
  • 10.2.3. By Therapeutic Areas
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Modality
      • 10.3.1.2.2. By Phase
      • 10.3.1.2.3. By Therapeutic Areas
  • 10.3.2. Colombia RNA Therapy Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Modality
      • 10.3.2.2.2. By Phase
      • 10.3.2.2.3. By Therapeutic Areas
  • 10.3.3. Argentina RNA Therapy Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Modality
      • 10.3.3.2.2. By Phase
      • 10.3.3.2.3. By Therapeutic Areas

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global RNA Therapy Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. IQVIA Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ICON Plc
• 15.3. Laboratory Corporation of America Holdings
• 15.4. Charles River Laboratories International, Inc.
• 15.5. PAREXEL International Corp.
• 15.6. Syneos Health
• 15.7. Medpace Holdings, Inc.
• 15.8. Novotech Inc.
• 15.9. PPD Inc.
• 15.10. Veristat, LLC.

16. Strategic Recommendations

17. About Us & Disclaimer